Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and pharmacokinetic study of minzasolmin ([14C]DLX313) in healthy male participants
NL-OMON59272Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of minzasolmin in Parkinson's disease (PD), sponsored by Novartis. Primary endpoint: Primary endpoint(s). Started Jul 2024; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59272.